AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model

• Published in: Protein engineering, design and selection Vol. 28; no. 10; pp. 467 - 480
• Main Authors: Stenderup, Karin, Rosada, Cecilia, Shanebeck, Kurt, Brady, William, Van Brunt, Michael P., King, Gordon, Marelli, Marcello, Slagle, Paul, Xu, Hengyu, Nairn, Natalie W., Johnson, Jeffrey, Wang, Aijun A., Li, Gary, Thornton, Kenneth C., Dam, Tomas N., Grabstein, Kenneth H.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.10.2015
• Subjects: Animals; Antibodies, Bispecific - immunology; Antibodies, Bispecific - pharmacokinetics; Antibodies, Bispecific - therapeutic use; Antibody Specificity; Disease Models, Animal; Female; Humans; Interleukin-23 - immunology; Interleukin-6 - immunology; Mice; Molecular Targeted Therapy; Psoriasis - drug therapy; Psoriasis - immunology; Rats; Transplantation, Heterologous; bispecific antibody; xenograft model; IL-23; psoriasis; IL-6

Targeting more than one molecule in multifactorial diseases involving several disease mediators may provide improved therapeutic efficacy. Psoriasis is a multifactorial disease in which interleukin (IL)-6 and IL-23 are important disease mediators because they facilitate development of Th17 cells; wi...